"15"^^ . . . . "tumour immunology" . "gene therapy" . . "Vaccination against two types (MHC I+ and MHC I-) of tumours induced by E6/E7 HPV16 viral oncogenes."@en . "Origin\u00E1ln\u00ED metoda genov\u00E9 terapie n\u00E1dor\u016F vyvolan\u00FDch onkogeny lidsk\u00E9ho papilomaviru HPV-16, konstrukce vakciny p\u0159ipraven\u00E9 z dendritick\u00FDch bun\u011Bk a ov\u011B\u0159en\u00ED jej\u00EDho profylaktick\u00E9ho \u00FA\u010Dinku."@cs . . . "NC7148" . "IL-12" . "0"^^ . . . "1"^^ . . . "Authors presented original methods of gene therapy of tumors induced by papiloma virus HPV-16, they constructed of vaccine prepared from dendritic cells and proved its prophylactic efficacy."@en . "0"^^ . "tumour immunology;gene therapy;HPV16;MHC I expression;IL-2;IL-12;GM-CSF;IFN gamma"@en . "2005-07-18+02:00"^^ . "This grant project is aimed at optimization of the immunotherapeutic protocols in two types of tumours (MHC I+ and MHC I-) induced by HPV16 E6/E7 oncogenes. The research will be focused on the effect of vaccines constructed in the previous grant project by insertion of IL-2 and GM-CSF genes into HPV16+ tumour cells The research will also be focused on the therapeutic effects of IL-2, IL-12 and GM-CSF cytokines administered separetely or together with dendritic cell-based vaccines. In the HPV16+,l MHC I-, metastasizing tumour MK16, the effect will be followed of peritumoral administration of IFN gamma, which is hypotratically capable to revert the MHC I- to MHC I+ tumour phenotype and thus enhance the tumour defence responce."@en . "MHC I expression" . "Vakciny proti dv\u011Bma typ\u016Fm (MHC I+ a MHC I-) n\u00E1dor\u016F vyvolan\u00FDch E6/E7 onkogeny viru HPV16." . . "HPV16" . . . "IL-2" . . . "C\u00EDlem grantov\u00E9ho projektu je optimalizace imunologick\u00E9 l\u00E9\u010Dby dvou typ\u016F n\u00E1dor\u016F (MHC I+ a MHC I-) vyvolan\u00FDch E6/E7 onkogeny viru HPV16. V\u00FDzkum bude zam\u011B\u0159en na \u00FA\u010Dinek vakcin p\u0159ipraven\u00FDch v r\u00E1mci p\u0159edchoz\u00EDho projektu vnesen\u00EDm genu pro IL-2 a GM-CSF do HPV16+ n\u00E1dorov\u00FDch bun\u011Bk. P\u0159edm\u011Btem v\u00FDzkumu bude rovn\u011B\u017E l\u00E9\u010Debn\u00FD \u00FA\u010Dinek rekombinantn\u00EDch IL-2, IL-12a GM-CSF cytokin\u016F podan\u00FDch samostatn\u011B nebo spolu s vakcinami z dendritick\u00FDch bun\u011Bk. U HPV16+, MHC I-, metastasuj\u00EDc\u00EDho n\u00E1doru MK16 bude sledov\u00E1n \u00FA\u010Dinek pod\u00E1n\u00ED IFN gamma,l kter\u00FD je hypoteticky schopen zm\u011Bnit MHC I- na MHC I+ fenotyp a t\u00EDm umo\u017Enit uplatn\u011Bn\u00ED MHC I restringovan\u00FDch slo\u017Eek imunitn\u00ED reakce." . "http://www.isvav.cz/projectDetail.do?rowId=NC7148"^^ . "GM-CSF" . . . . "15"^^ . .